Phase 2 randomised trial, repurposing Danazol and VBaP in low-risk myelodysplastic syndrome: REPAIR MDS

被引：0
|
作者：
Raghavan, Manoj [3 ]
Jenkins, Stephen [1 ,2 ]
Wintrich, Sophie [4 ]
Drayson, Mark [3 ]
Bunce, Chris [3 ]
Culligan, Dominic [5 ]
Kulasekararaj, Austin [6 ,7 ]
Wiseman, Dan [8 ,9 ]
Foster, Bethany [1 ]
Dunn, Janet [1 ]
机构：
[1] Univ Warwick, Coventry, W Midlands, England
[2] Dudley Grp NHS Fdn Trust, Dudley, England
[3] Univ Birmingham, Birmingham, W Midlands, England
[4] MDS UK Support Grp, London, England
[5] Aberdeen Royal Infirm, Aberdeen, Scotland
[6] Kings Coll Hosp London, London, England
[7] Kings Coll London, London, England
[8] CRCUK Manchester, Machester, England
[9] Christie NHS Fdn Trust, Machester, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH23-EP17
引用
收藏
页码：153 / 153
页数：1
相关论文
共 50 条
  • [1] Phase 2 randomised trial, repurposing Danazol and VBaP in low-risk myelodysplastic syndrome: REPAIR MDS
    Raghavan, Manoj
    Jenkins, Stephen
    Wintrich, Sophie
    Drayson, Mark
    Bunce, Chris
    Culligan, Dominic
    Kulasekararaj, Austin
    Wiseman, Dan
    Foster, Bethany
    Dunn, Janet
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 153 - 153
  • [2] Treatment of myelodysplastic syndrome (MDS) with cytokine immunotherapy for low-risk MDS
    Kadia, Tapan M.
    Kantadian, Hagop
    Verstovsek, Srdan
    Newman, Beth
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    BLOOD, 2007, 110 (11) : 438A - 438A
  • [3] Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
    Oliva, Esther N.
    Alati, Caterina
    Santini, Valeria
    Poloni, Antonella
    Molteni, Alfredo
    Niscola, Pasquale
    Salvi, Flavia
    Sanpaolo, Grazia
    Balleari, Enrico
    Germing, Ulrich
    Fenaux, Pierre
    Stamatoullas, Aspasia
    Palumbo, Giuseppe A.
    Salutari, Prassede
    Impera, Stefana
    Avanzini, Paolo
    Cortelezzi, Agostino
    Liberati, Anna Marina
    Carluccio, Paola
    Buccisano, Francesco
    Voso, Maria Teresa
    Mancini, Stefano
    Kulasekararaj, Austin
    Morabito, Fortunato
    Bocchia, Monica
    Cufari, Patrizia
    Spiriti, Maria Antonietta Aloe
    Santacaterina, Irene
    D'Errigo, Maria Grazia
    Bova, Irene
    Zini, Gina
    Latagliata, Roberto
    LANCET HAEMATOLOGY, 2017, 4 (03): : E127 - E136
  • [4] Alemtuzumab treatment for aplastic anemia (AA) and low-risk myelodysplastic syndrome (MDS): Preliminary results
    Lee, Je-Hwan
    Choi, Seong-Jun
    Lee, Jung-Hee
    Seol, Miee
    Lee, Young-Shin
    Sim, Soo-Yung
    Ryu, Seong-Gil
    Kang, Young-Ah
    Lee, Kyoo-Hyung
    BLOOD, 2007, 110 (11) : 438A - 438A
  • [5] Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS)
    Fenaux, P
    SEMINARS IN ONCOLOGY, 2005, 32 (04) : S11 - S15
  • [6] Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk Myelodysplastic syndrome (MDS): Update including extended treatment
    Kantarjian, Hagop
    Fenaux, Pierre
    Sekeres, Milckael A.
    Becker, Pamela
    Boruchov, Adam
    Bowen, David
    Larson, Richard
    Lyons, Roger
    Muus, Petra
    Shammo, Jamile
    Ehrman, Michael
    Hu, Kuolung
    Nichol, Janet
    BLOOD, 2007, 110 (11) : 81A - 81A
  • [7] Randomised Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial
    Oliva, Esther Natalie
    Alati, Caterina
    Santini, Valeria
    Poloni, Antonella
    Riva, Marta
    Niscola, Pasquale
    Giai, Valentina
    Sanpaolo, Grazia
    Balleari, Enrico
    Crisa, Elena
    Ferrero, Dario
    Germing, Ulrich
    Fenaux, Pierre
    Palumbo, Giuseppe A.
    Salutari, Prassede
    Impera, Stefana
    Capodanno, Isabella
    Reda, Gianluigi
    Liberati, Anna Marina
    Molteni, Alfredo
    Specchia, Giorgina
    Buccisano, Francesco
    Voso, Maria Teresa
    Mancini, Stefano
    Bocchia, Monica
    Candoni, Anna
    Martino, Bruno
    Cufari, Patrizia
    D'Errigo, Maria Grazia
    Zini, Gina
    Latagliata, Roberto
    BLOOD, 2019, 134
  • [8] Delayed response to lenalidomide in International Prognostic Scoring System (IPSS) low-risk myelodysplastic syndrome (MDS)
    Garcia, A. Mejia
    Asija, A.
    Besa, E. C.
    Giagounidis, A.
    Fonseca, G. A.
    LEUKEMIA RESEARCH, 2013, 37 : S111 - S111
  • [9] Leukaemia cutis in a patient with low-risk myelodysplastic syndrome
    Lin, Jinran
    Zhang, Qiao'an
    Chen, Minghua
    JOURNAL OF DERMATOLOGY, 2010, 37 : 42 - 42
  • [10] The role of rHuEpo in low-risk myelodysplastic syndrome patients
    Rigolin, GM
    Castoldi, G
    LEUKEMIA & LYMPHOMA, 2005, 46 (06) : 823 - 831
12345